Press "Enter" to skip to content

Gilead Sciences to Present Gilead-Kite Oncology portfolio

Gilead Sciences Inc shares advanced 1.24% to $69.35 Thursday. This proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.06% to 4,159.12 and the Dow Jones Industrial Average DJIA rising 0.55% to 34,084.15. The stock’s rise snapped a two-day losing streak.

Gilead Sciences Inc. closed $9.96 below its 52-week high ($79.31), which the company achieved on June 8th. The stock outperformed some of its competitors Thursday, as Johnson & Johnson JNJ rose 0.58% to $171.07, Merck & Co. Inc. MRK rose 0.38% to $79.66, and AbbVie Inc. ABBV rose 1.09% to $117.11. Trading volume (6.5 M) remained 762,501 below its 50-day average volume of 7.3 M.

Gilead Sciences, Inc.and Kite, a Gilead Company, that 16 abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented at the American Society of Clinical Oncology Annual Meeting from June 4-8, 2021. The abstracts, including two oral presentations, expand on the clinical profiles of Gilead’s antibody-drug conjugate, as well as Kite’s chimeric antigen receptor T-cell therapies across a range of cancers, including in existing indications and for investigational uses.

Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences Inc said that Gilead-Kite Oncology is quickly advancing transformative science for people facing historically difficult-to-treat cancers. The first-in-class, TROP-2 directed ADC therapy is having an impact on people with metastatic triple-negative breast and urothelial cancers. The data at ASCO will add insight into its utility in TNBC in both monotherapy and future combination treatment approaches.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *